Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience

Basit Öğe Kaydı
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authoridGozukara Bag, Harika Gozde/0000-0003-1208-4072
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidGozukara Bag, Harika Gozde/ABG-7588-2020
dc.contributor.authorBerber, Ilhami
dc.contributor.authorKuku, Irfan
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKaya, Emin
dc.contributor.authorBag, Harika Gozukara
dc.contributor.authorNizam, Ilknur
dc.contributor.authorKoroglu, Mustafa
dc.date.accessioned2024-08-04T20:41:23Z
dc.date.available2024-08-04T20:41:23Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractHyperleukocytosis is defined as WBC count above 100,000/mm(3) in peripheral blood. Increased WBC count leads to leukocyte aggregation, increased blood viscosity, and consequently results in stasis in small blood vessels. Ultimate neurological, pulmonary, gastrointestinal complications, coagulopathy, and tumor lysis syndrome cause increase in morbidity and mortality. Leukapheresis is a treatment modality used for hyperleukocytosis. In patients presenting with hyperleukocytosis the indications for leukapheresis were accepted as having symptoms of leukostasis and prophylactic. Indications for leukapheresis in prophylactic group evaluated according to WBC count. We report a single center experience about leukapheresis in managing 31 AML patients with hyperleukocytosis. In addition to demographic characteristics, disease-related clinical and laboratory findings of the patients were recorded. Survival rates were also calculated. Ten patients were female. The most common of AML subtype was AML-M2. The median number of leukapheresis per patient was 2 and totally 60 leukapheresis cycles were performed in all patients. There was a significant decrease in WBC count and LDH level after leukapheresis as compared with the baseline values (p<0.05). Early and total mortality were 16.1% and 58.0%, respectively. Alive and died patients were evaluated according to baseline WBC, LDH; increased WBC count and LDH level were found in died patients (p<0.05). According to leukapheresis indications, patients were divided into two groups: 14 patients in symptomatic leukostasis, 17 patients in prophylaxis. No statistically significant differences were noted between both groups in leukapheresis effectiveness, mean survival time, early and total mortality rate (p>0.05). None of our patients suffered serious side effects and tumor lysis syndrome during or after apheresis. Leukapheresis is an effective and safe approach to reduce WBC counts in patients with AML with hyperleukocytosis. Further evidence-based data obtained from larger sample sizes are required to better understand the impact of prophylaxis leukapheresis on early and total mortality of AML patients with hyperleukocytosis. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2015.03.015
dc.identifier.endpage190en_US
dc.identifier.issn1473-0502
dc.identifier.issue2en_US
dc.identifier.pmid25843763en_US
dc.identifier.scopus2-s2.0-84952639229en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage185en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2015.03.015
dc.identifier.urihttps://hdl.handle.net/11616/97091
dc.identifier.volume53en_US
dc.identifier.wosWOS:000366778100014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLeukapheresisen_US
dc.subjectAcute myeloid leukemiaen_US
dc.subjectHyperleukocytosisen_US
dc.titleLeukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu